Performance enhancement in the workplace: why and when healthy individuals should disclose their reliance on pharmaceutical cognitive enhancers

Frontiers in Systems Neuroscience
Mirko D Garasic, Andrea Lavazza

Abstract

The use of pharmaceuticals cognitive enhancers (PCE) has been stirring growing interest, not only in the scientific domain but also in the popular media, and has probably had some increase recently in academic, professional and military quarters. So this phenomenon is deemed as a normal procedure aimed at improving the performance of an individual as well as the overall standards of an organization. Although the vast majority of countries have some kind of restrictions to reduce the wide non-medical usage of PCE, these can be overcome quite easily. In arguing for our explicit claim that, in many contexts, the use of cognitive enhancers should be disclosed-as a moral and socially relevant duty-we maintain that PCE present typical, or at least not rare, properties. The features are the following: (a) the enhancer has acute and/or chronic effects. In the first case, shortly after taking the drug the performance is significantly better than average; in the second case, there is a growing or lasting effect, which, however, is poised to diminish when one stops taking the drug; (b) those effects are significant (there is a difference in the outcome considered between taking and not taking the drug) and sometimes dramatic; and (c) a th...Continue Reading

References

Dec 28, 2000·Journal of American College Health : J of ACH·Q Babcock, T Byrne
Jan 17, 2004·Journal of the American Academy of Child and Adolescent Psychiatry·Kerstin KonradBeate Herpertz-Dahlmann
Apr 22, 2004·Nature Reviews. Neuroscience·Martha J FarahPaul Root Wolpe
Aug 28, 2004·The Milbank Quarterly·Maxwell J Mehlman
May 20, 2005·Journal of American College Health : J of ACH·Christian J TeterSally K Guthrie
Dec 22, 2007·Nature·Barbara Sahakian, Sharon Morein-Zamir
Mar 21, 2008·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Cristina LanniStefano Govoni
Jun 24, 2008·The American Journal of Bioethics : AJOB·Michael B RussoJohn A Caldwell
Nov 5, 2008·Journal of American College Health : J of ACH·Alan D DeSantisSeth M Noar
Nov 26, 2008·Psychopharmacology·Natalie L MarchantJennifer M Rusted
Dec 9, 2008·Nature·Henry GreelyMartha J Farah
Jan 21, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Nora D VolkowJames M Swanson
Jun 12, 2013·Frontiers in Neuroscience·Claire Advokat, Mindy Scheithauer
Dec 18, 2013·Pharmacological Reviews·Suzanne WoodStephan G Anagnostaras
Sep 13, 2014·European Archives of Psychiatry and Clinical Neuroscience·Andreas G FrankeKlaus Lieb

❮ Previous
Next ❯

Citations

Jun 4, 2019·The International Journal of Neuropsychopharmacology·Nadia R P W HuttenKim P C Kuypers

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

The Canadian Veterinary Journal. La Revue Vétérinaire Canadienne
R M Dixon
Sovetskaia meditsina
L V Metelitsa, G V Dvorkin
The Canadian Journal of Cardiology
Eldon R Smith
© 2021 Meta ULC. All rights reserved